Healthcare services provider AdaptHealth Corp. (NASDAQ: AHCO) reported Q3 2026 results beating Wall Street’s revenue expectations, but sales fell by 9.1% year on year to $745.6 million. The company expects the full year’s revenue to be around $2.89 billion, close to analysts’ estimates. Its non-GAAP profit of $0.07 per share was significantly above analysts’ consensus estimates.

Is now the time to buy AHCO? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

AdaptHealth’s third quarter saw a positive market response, with management crediting improved performance in its largest capitated contract and ongoing cost controls as central drivers. CEO Suzanne Foster explained that the company achieved a significant margin swing in its West Coast operations and tightened labor models, noting, “We have lowered our costs even with utilization still elevated and while exceeding our service level requirements and commitments.” The quarter also saw an $8 million manufacturer rebate arrangement that partially offset a previously anticipated $30 million EBITDA headwind, while strong organic growth was primarily driven by the new capitated contract, with base business organic growth contributing only 2.1 percentage points of the total 12.8% organic growth in Sleep, Respiratory, and Wellness at Home segments.

Looking ahead, AdaptHealth’s guidance rests on continued improvement in margins from the largest capitated contract (which was still below long-term targets in Q3), progress in securing price adjustments with partners, and a focus on expense discipline following the Diabetes Health divestiture. Foster emphasized the strategic value of expanding preferred provider and capitated agreements, as well as investments in digital tools to streamline patient care. CFO Harriss Currie cautioned that expectations for 2027 hinge on maintaining cost controls and organic growth, stating, “Expect a modest improvement in margin as we don’t allow our costs to outrun revenue growth.”

Key insights from management’s remarks

Management attributed the quarter’s results to operational turnaround in its largest capitated contract, partial recovery of manufacturer rebates, and disciplined labor cost reductions.

• Capitated contract profitability: The turnaround in AdaptHealth’s largest capitated contract, especially in West Coast operations, shifted from a loss in the prior quarter to a positive adjusted EBITDA contribution, aided by better cost alignment and a reduction in temporary staff and labor. The Q3 margin was approximately 10%, with a run-rate of about 14% at quarter end, still below the 20% margin target expected by the end of next year.
• Rebates offset pricing headwinds: Management secured an $8 million benefit from a manufacturer rebate arrangement after a contract termination and price increase earlier in the year, which partially offset a $30 million EBITDA headwind and improved margins in the quarter.
• Labor and cost discipline: Headcount reductions of over 12% in the capitated contract segment, as well as broader labor optimization, contributed to increased efficiency and stabilized operating expenses. Management expects further improvements as cost structures are refined.
• Portfolio streamlining: The company advanced the sale of its Diabetes Health business to Cardinal Health, refocusing its core on Sleep, Respiratory, and Wellness at Home. While these segments have higher growth and margin potential, adjusted EBITDA margin declined year-over-year in the quarter (from 21.7% to 19%). Roughly half of previously allocated corporate overhead to Diabetes Health is expected to dissipate post-sale.
• Digital tools and enterprise sales: The MyAPP digital platform grew to more than 615,000 registered users, up about 20% from last quarter and nearly double where the company ended last year, with new AI-powered mask-fitting tools showing strong adoption. The enterprise sales team signed four preferred provider agreements with large health systems, and two new regional capitated contracts, broadening the company’s payer and referral base.

Drivers of future performance

Management’s outlook centers on improved capitated contract margins (still below targets in Q3 but expected to expand), cost containment, and the transition to a streamlined core business after divestiture.

• Capitated margin expansion: Management expects margins on its largest capitated contract to reach 20% by the end of next year, driven by better utilization management, ongoing partner negotiations for pricing adjustments, and continuous workflow improvements. The Q3 margin was approximately 10%, with a run-rate of about 14% at quarter end; any successful pricing adjustments would provide incremental upside.
• Expense control focus: The company’s expense discipline, including lower headcount and operational overhead, is expected to support future margin recovery and offset stranded costs from the Diabetes Health divestiture. CFO Harriss Currie highlighted that cost control will be critical to preventing expenses from outpacing revenue growth, though adjusted EBITDA margin declined year-over-year in Q3.
• Core business organic growth: AdaptHealth anticipates a return to more normalized organic growth rates in Sleep, Respiratory, and Wellness at Home as the PCS business winds down and as new preferred provider agreements and digital initiatives ramp up. Most organic growth in the quarter was driven by the new capitated contract, with base business organic growth at 2.1 percentage points; base business referral volumes are expected to improve, supporting top-line growth.

Catalysts in upcoming quarters

In the coming quarters, our analyst team will be tracking (1) progress on renegotiating pricing and utilization terms in the largest capitated contract (which remains below long-term margin targets), (2) reduction and absorption of stranded corporate overhead following the Diabetes Health divestiture, and (3) scaling of digital initiatives and preferred provider agreements. Execution in these areas, along with potential margin recovery in the core segments, will be crucial signposts for AdaptHealth’s trajectory.

AdaptHealth currently trades at $6.30, up from $5.91 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

High quality stocks for all market conditions

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.